Another publication on the way!! In the meantime, check out our preprint: www.biorxiv.org/content/10.6...
biorxiv.org
Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer
Up to 40% of patients with estrogen receptor positive breast cancer will experience relapse, either while on endocrine therapy (ET) or after ET is completed. A major contributor to ET failure is the p...